全球头颈癌市场评估：依治疗类型、给药途径、药物类别、销售管道、地区、机会与预测（2017-2031）

全球头颈癌市场规模预计到2023年将达到22.5亿美元，到2031年将达到37.6亿美元，2024-2031年预测期间复合年增长率为6.62%。随着对疾病和治疗方法的了解的增加，市场正在显示出显着的成长和演变。

头颈癌，包括发生在口腔、咽部和喉部的肿瘤，给全世界带来了巨大的医疗负担。吸烟和饮酒、人类乳突病毒 (HPV) 感染和环境因素等危险因子会导致这些癌症的发生。全球头颈癌市场受到发病率上升、诊断方法改进和创新治疗方法开发等因素的推动。免疫疗法和标靶疗法的最新进展为患者带来了希望。这些新疗法，加上对精准医疗和个人化治疗计划的日益关注，正在改变市场。市场上的主要参与者正在投资于研发，以推出新的治疗方法并扩大其产品组合。此外，人们对早期检测和预防重要性的认识不断提高也促进了市场的成长。全球头颈癌市场充满活力且快速发展，重点是透过先进的治疗方案和早期干预策略来改善患者的治疗结果。

免疫疗法的新疗法

Elsevier发表的一篇文章报导，免疫疗法的引入彻底改变了头颈癌的治疗。这些治疗的重点是调节介导肿瘤细胞和 T 淋巴细胞之间相互作用的免疫抑制途径。2022 年 8 月发表在 Frontiers 上的一篇文章表明，免疫疗法具有提供持久抗肿瘤作用的巨大潜力，特别是在治疗头颈部鳞状细胞癌方面。多种免疫治疗方法用于治疗头颈鳞状细胞癌（HNSCC），包括共刺激激动剂、免疫检查点抑制剂、抗原疫苗、过继性T 细胞移植（ACT）、溶瘤病毒治疗和EGFR 标靶治疗。例如，Merck于2023年11月宣布，FDA批准Merck的抗PD-1疗法Keytruda与gemcitabine、cisplatin一起用于治疗局部晚期不可切除或转移性胆道癌（BTC）。

大量投资于研发

近年来，全球头颈癌相关的研发活动迅速增加。这种关注度的增加是由于多种因素造成的。例如，全球头颈癌发生率的上升增加了对预防、早期检测和治疗策略进行更全面研究的需求。包括基因组学和标靶治疗在内的医疗技术的进步也为个人化和更有效的治疗开闢了新途径。

例如，2023年10月，处于后期临床开发的生物技术公司Nanobiotix宣布开始NANORAY-312的患者入组，这是一项测试NBTXR3安全性和有效性的3期临床试验。该候选药物在有效治疗老年人头颈癌方面显示出巨大潜力。2022 年 9 月，专门从事免疫疗法开发和行销的临床阶段生物技术公司 Genexine Inc. 宣布在 2 期临床试验中开始患者给药。包括GX-188E（治疗性DNA疫苗）、GX-I7（长效白细胞介素7）、OpdivoR（纳武单抗）和PD-1免疫检查点抑制剂在内的三药联合疗法用于治疗转移性或復发性疾病。头颈鳞状细胞癌。

本报告研究和分析了全球头颈癌市场，提供市场规模和预测、市场动态、主要参与者趋势和前景等。

目录

第一章研究方法论

第二章 专案范围与定义

第三章 COVID-19对全球头颈癌市场的影响

第 4 章执行摘要

第五章 全球头颈癌市场展望（2017-2031）

• 市场规模及预测
  • 金钱数额
  • 数量
• 按治疗类型
  • 化学处理
  • 免疫疗法
  • 靶向治疗
• 按给药途径
  • 注射
  • 口服
• 按药物类别
  • EGFR抑制剂
  • 有丝分裂抑制剂
  • 抗PD-1单株抗体
  • 其他
• 按分销渠道
  • 零售店、专卖药局
  • 医院药房
  • 网上药店
• 按地区
  • 北美
  • 欧洲
  • 亚太地区
  • 南美洲
  • 中东/非洲
• 市场占有率：依公司划分（2023 年）

第六章全球头颈癌市场展望：按地区（2017-2031）

• 北美
  • 市场规模及预测
  • 按治疗类型
  • 按给药途径
  • 按药物类别
  • 按分销渠道
  • 美国
• 欧洲
  • 德国
  • 法国
  • 义大利
  • 英国
  • 俄罗斯
  • 荷兰
  • 西班牙
  • 土耳其
  • 波兰
• 南美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 亚太地区
  • 印度
  • 中国
  • 日本
  • 澳大利亚
  • 越南
  • 韩国
  • 印度尼西亚
  • 菲律宾
• 中东/非洲
  • 沙乌地阿拉伯
  • 阿拉伯联合酋长国
  • 南非

第 7 章 市场测绘（2023）

• 按治疗类型
• 按给药途径
• 按分销渠道
• 按地区

第八章 宏观环境与产业结构

• 供需分析
• 进出口分析 - 数量和价值
• 供应/价值链分析
• PESTEL 分析
• 波特五力分析

第九章市场动态

• 增长动力
• 成长限制因素（问题、限制因素）

第十章 监理框架与创新

• 临床试验
• 专利情况
• 监管审批
• 创新/新技术

第十一章 主要公司情况

• 前 5 名市场领导者的竞争矩阵
• 前 5 名市场领导者的市场收入分析（2023 年）
• 併购/合资（如适用）
• SWOT分析（5家进入市场的公司）
• 专利分析（如果适用）

第12章价格分析

第十三章案例研究

第十四章 主要公司展望

• F. Hoffmann-La Roche Ltd.
• Eli Lilly and Company
• Sanofi
• Merck & Co., Inc.
• Clinigen Group plc.
• Bristol-Myers Squibb Company
• AstraZeneca
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd
• GlaxoSmithKline plc.

第十五章 战略建议

第十六章 关于我们公司、免责声明

Global head and neck cancer market size was valued at USD 2.25 billion in 2023, and is expected to reach USD 3.76 billion in 2031, with a CAGR of 6.62% for the forecast period between 2024 and 2031F. The global head and neck cancer market encompasses a diverse range of treatments and therapies aimed at addressing the complex and challenging landscape of cancers that affect the head and neck regions. The market is experiencing significant growth and evolution as the understanding of the disease and its treatment options continue to advance.

Head and neck cancers, which include tumors in the oral cavity, pharynx, larynx, and other areas, represent a substantial global healthcare burden. Risk factors such as tobacco and alcohol consumption, human papillomavirus (HPV) infection, and environmental factors contribute to the development of these cancers. The global market for head and neck cancer is driven by factors such as increasing incidence rates, improved diagnostic methods, and the development of innovative therapeutic approaches. Recent advancements in immunotherapy and targeted therapies have brought hope to patients. These emerging treatment modalities, along with a growing focus on precision medicine and personalized treatment plans, are transforming the market. Key market players invest in research and development to introduce novel therapies and expand their product portfolios. Moreover, the increasing awareness about the importance of early detection and prevention contributes to market growth. The global head and neck cancer market is dynamic and rapidly evolving, focusing on improving patient outcomes through advanced treatment options and early intervention strategies.

Novel Therapies in Immunotherapy

As per an article published by Elsevier, it was reported that the introduction of immunotherapies has brought about a notable transformation in the treatment of head and neck cancer. These therapies are primarily focused on modulating the immunosuppressive pathways that mediate the interaction between tumor cells and T-lymphocytes. An article published in August 2022 by Frontiers highlighted the significant potential of immunotherapies to generate enduring antitumor effects, particularly in the context of treating head and neck squamous cell carcinomas. Various immunotherapy approaches, including the use of costimulatory agonists, immune checkpoint inhibitors, antigenic vaccines, adoptive T cell transfer (ACT), oncolytic virus therapy, and EGFR-targeted therapy, are now being employed for the management of head and neck squamous cell carcinomas (HNSCC). For Instance, Merck declared in November 2023 that the U.S. Food and Drug Administration (FDA) has given the green light to KEYTRUDA, Merck's anti-PD-1 therapy, along with gemcitabine and cisplatin, for addressing individuals dealing with locally advanced unresectable or metastatic biliary tract cancer (BTC).

Substantial Investment in Research and Development

In recent years, there has been a noticeable surge in research and development activities related to global head and neck cancer. The increased focus can be attributed to several factors, such as the rising incidence of head and neck cancer cases worldwide has spurred the need for more comprehensive research into prevention, early detection, and treatment strategies. Also, advancements in medical technologies, including genomics and targeted therapies, have opened new avenues for personalized and more effective treatments.

For instance, In October 2023, Nanobiotix, a biotechnology company in the later stages of clinical development, announced the initiation of patient enrollment for NANORAY-312, a phase III clinical trial to examine the safety and effectiveness of NBTXR3. The drug candidate has demonstrated significant promise in effectively treating head and neck cancer among elderly patients. In September 2022, Genexine Inc, a biotechnology company in the clinical stage focused on developing and marketing immunotherapies, announcing the initiation of patient dosing in a phase II clinical trial. The company employed a triple combination therapy involving GX-188E (a therapeutic DNA vaccine), GX-I7 (a long-acting interleukin 7), OpdivoR (nivolumab), and PD-1 immune checkpoint inhibitor, for addressing metastatic or recurrent head and neck squamous cell carcinoma.

Partnership and Acquisitions Between Key Market Players

In the dynamic landscape of global head and neck cancer market, strategic partnerships among key industry players have emerged as pivotal instruments for innovation and progress. These collaborations, characterized by shared expertise and resources, aim to advance research, develop cutting-edge therapies, and improve patient outcomes. Through such alliances, companies combine their strengths in drug development, medical technology, and clinical research to accelerate the discovery and delivery of novel treatments. These partnerships often foster synergies, allowing the pooling of knowledge, technologies, and financial resources. They facilitate the streamlining of regulatory processes and establishing wider access to global markets. Ultimately, these strategic alliances drive the evolution of more effective therapies, early detection methods, and personalized treatment solutions in the fight against head and neck cancers. The collective efforts of these collaborations hold promising potential for shaping the future of cancer care. For Instance, In November 2022, Fulgent Genetics, Inc., a technology-driven genetic testing company situated in the United States, revealed its acquisition of Fulgent Pharma Holdings, Inc. The acquisition aimed to offer a unified solution in the region's fight against head and neck cancer.

Strategic Initiatives by Key Players

Key players in the global head and neck cancer therapeutics market have been strategically focused on several initiatives to enhance treatment outcomes and address unmet medical needs. These initiatives primarily revolve around innovative research and development efforts, collaborative partnerships, and technological advancements. Companies are heavily investing in novel therapies, including immunotherapies and targeted therapies, to improve patient survival rates and reduce adverse effects. Additionally, these players are expanding their product portfolios through mergers, acquisitions, and licensing agreements to broaden their market presence and offer comprehensive solutions. They emphasize personalized medicine approaches, aiming to tailor treatments based on individual patient characteristics. For instance, in April 2023, Eisai initiated the "Made of More" initiative to foster a community for individuals affected by head and neck cancer. Additionally, Eisai is presently conducting trials combining its approved cancer medication, Lenvima, with other oncology drugs for treating head and neck cancers.

Impact of COVID-19

The head and neck cancer therapeutics market experienced significant disruption due to the COVID-19 pandemic. The health crisis particularly affected highly immunocompromised cancer patients, leading to strict lockdowns that hindered their access to essential treatments. Additionally, cancer screenings, preventive healthcare services, and elective surgeries were often delayed, except in cases where the benefits outweighed the risks and to prioritize hospital resources for COVID-19 care.

An article published by NCBI (National Center for Biotechnology Information) highlighted that elective surgeries, including head and neck cancer surgeries, were postponed in many countries. Approximately 60% of scheduled outpatient visits at the European Institute of Oncology (IEO) were delayed. The diversion of medical resources to attend COVID-19 patients resulted in a setback for head and neck cancer treatment, leading to increased tumor growth, recurrence, and high mortality rates. As a result, the COVID-19 pandemic significantly impacted the head and neck cancer diagnostics market.

Key Players Landscape and Outlook

With ongoing research and development, innovative treatments targeting PD-1/PD-L1 pathways have redefined the market. Additionally, companies are emerging with novel therapies, fostering a competitive market. The outlook is promising, emphasizing precision medicine, combination therapies, and biomarker research. Key players are intensifying efforts in clinical trials and strategic collaborations, underscoring a robust drive towards personalized and more effective treatments, potentially transforming the head and neck cancer market.

In August 2022, Genexine Inc, a clinical-stage biotech firm specializing in immunotherapeutics, announced the initiation of patient dosage in a phase II clinical trial. Employing a triple combination therapy comprising GX-188E (a therapeutic DNA vaccine), GX-I7 (a prolonged-acting interleukin 7), and OpdivoR (nivolumab), a PD-1 immune checkpoint inhibitor, the company aimed to treat metastatic head and neck squamous cell carcinoma.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Impact of COVID-19 on Global Head and Neck Cancer Market

4. Executive Summary

5. Global Head and Neck Cancer Market Outlook, 2017-2031F

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
  • 5.1.2. By Volume
• 5.2. By Therapy Type
  • 5.2.1. Chemotherapy
  • 5.2.2. Immunotherapy
  • 5.2.3. Targeted Therapy
• 5.3. By Route of Administration
  • 5.3.1. Injectable
  • 5.3.2. Oral
• 5.4. By Drug Class
  • 5.4.1. EGFR Inhibitors
  • 5.4.2. Mitotic Inhibitors
  • 5.4.3. Anti-PD-1 Monoclonal Antibodies
  • 5.4.4. Others
• 5.5. By Distribution Channel
  • 5.5.1. Retail and Specialty Pharmacies
  • 5.5.2. Hospital Pharmacies
  • 5.5.3. Online Pharmacies
• 5.6. By Region
  • 5.6.1. North America
  • 5.6.2. Europe
  • 5.6.3. Asia Pacific
  • 5.6.4. South America
  • 5.6.5. Middle East & Africa
• 5.7. By Company Market Share (%), 2023

6. Global Head and Neck Cancer Market Outlook, By Region, 2017-2031F

• 6.1. North America*
  • 6.1.1. Market Size & Forecast
    • 6.1.1.1. By Value
    • 6.1.1.2. By Volume
  • 6.1.2. By Therapy Type
    • 6.1.2.1. Chemotherapy
    • 6.1.2.2. Immunotherapy
    • 6.1.2.3. Targeted Therapy
  • 6.1.3. By Route of Administration
    • 6.1.3.1. Injectable
    • 6.1.3.2. Oral
  • 6.1.4. By Drug Class
    • 6.1.4.1. EGFR Inhibitors
    • 6.1.4.2. Mitotic Inhibitors
    • 6.1.4.3. Anti-PD-1 Monoclonal Antibodies
    • 6.1.4.4. Others
  • 6.1.5. By Distribution Channel
    • 6.1.5.1. Retail and Specialty Pharmacies
    • 6.1.5.2. Hospital Pharmacies
    • 6.1.5.3. Online Pharmacies
  • 6.1.6. United States*
    • 6.1.6.1. Market Size & Forecast
    • 6.1.6.1.1. By Value
    • 6.1.6.1.2. By Volume
    • 6.1.6.2. By Therapy Type
    • 6.1.6.2.1. Chemotherapy
    • 6.1.6.2.2. Immunotherapy
    • 6.1.6.2.3. Targeted Therapy
    • 6.1.6.3. By Route of Administration
    • 6.1.6.3.1. Injectable
    • 6.1.6.3.2. Oral
    • 6.1.6.4. By Drug Class
    • 6.1.6.4.1. EGFR Inhibitors
    • 6.1.6.4.2. Mitotic Inhibitors
    • 6.1.6.4.3. Anti-PD-1 Monoclonal Antibodies
    • 6.1.6.4.4. Others
    • 6.1.6.5. By Distribution Channel
    • 6.1.6.5.1. Retail and Specialty Pharmacies
    • 6.1.6.5.2. Hospital Pharmacies
    • 6.1.6.5.3. Online Pharmacies
    • 6.1.6.6. By Region
    • 6.1.6.6.1. North America
    • 6.1.6.6.2. Europe
    • 6.1.6.6.3. Asia-Pacific
    • 6.1.6.6.4. South America
    • 6.1.6.6.5. Middle East & Africa
    • 6.1.6.7. Canada
    • 6.1.6.8. Mexico

All segments will be provided for all regions and countries covered:

• 6.2. Europe
  • 6.2.1. Germany
  • 6.2.2. France
  • 6.2.3. Italy
  • 6.2.4. United Kingdom
  • 6.2.5. Russia
  • 6.2.6. Netherlands
  • 6.2.7. Spain
  • 6.2.8. Turkey
  • 6.2.9. Poland
• 6.3. South America
  • 6.3.1. Brazil
  • 6.3.2. Mexico
  • 6.3.3. Argentina
• 6.4. Asia-Pacific
  • 6.4.1. India
  • 6.4.2. China
  • 6.4.3. Japan
  • 6.4.4. Australia
  • 6.4.5. Vietnam
  • 6.4.6. South Korea
  • 6.4.7. Indonesia
  • 6.4.8. Philippines
• 6.5. Middle East & Africa
  • 6.5.1. Saudi Arabia
  • 6.5.2. UAE
  • 6.5.3. South Africa

7. Market Mapping, 2023

• 7.1. By Therapy Type
• 7.2. By Route of Administration
• 7.3. By Distribution Channel
• 7.4. By Region

8. Macro Environment and Industry Structure

• 8.1. Supply Demand Analysis
• 8.2. Import Export Analysis - Volume and Value
• 8.3. Supply/Value Chain Analysis
• 8.4. PESTEL Analysis
  • 8.4.1. Political Factors
  • 8.4.2. Economic System
  • 8.4.3. Social Implications
  • 8.4.4. Technological Advancements
  • 8.4.5. Environmental Impacts
  • 8.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
• 8.5. Porter's Five Forces Analysis
  • 8.5.1. Supplier Power
  • 8.5.2. Buyer Power
  • 8.5.3. Substitution Threat
  • 8.5.4. Threat from New Entrant
  • 8.5.5. Competitive Rivalry

9. Market Dynamics

• 9.1. Growth Drivers
• 9.2. Growth Inhibitors (Challenges, Restraints)

10. Regulatory Framework and Innovation

• 10.1. Clinical Trials
• 10.2. Patent Landscape
• 10.3. Regulatory Approvals
• 10.4. Innovations/Emerging Technologies

11. Key Players Landscape

• 11.1. Competition Matrix of Top Five Market Leaders
• 11.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
• 11.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
• 11.4. SWOT Analysis (For Five Market Players)
• 11.5. Patent Analysis (If Applicable)

12. Pricing Analysis

13. Case Studies

14. Key Players Outlook

• 14.1. F. Hoffmann-La Roche Ltd.
  • 14.1.1. Company Details
  • 14.1.2. Key Management Personnel
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As reported)
  • 14.1.5. Key Market Focus & Geographical Presence
  • 14.1.6. Recent Developments
• 14.2. Eli Lilly and Company
• 14.3. Sanofi
• 14.4. Merck & Co., Inc.
• 14.5. Clinigen Group plc.
• 14.6. Bristol-Myers Squibb Company
• 14.7. AstraZeneca
• 14.8. Takeda Pharmaceutical Company Limited
• 14.9. Teva Pharmaceutical Industries Ltd
• 14.10. GlaxoSmithKline plc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

15. Strategic Recommendations

16. About Us & Disclaimer

List of Tables

• Table 1. Pricing Analysis of Products from Key Players
• Table 2. Competition Matrix of Top 5 Market Leaders
• Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. Global Head and Neck Cancer Market, By Value, In USD Billion, 2017-2031F
• Figure 2. Global Head and Neck Cancer Market, By Volume, In Million Units, 2017-2031F
• Figure 3. Global Head and Neck Cancer Market Share (%), By Therapy Type, 2017-2031F
• Figure 4. Global Head and Neck Cancer Market Share (%), By Route of Administration, 2017-2031F
• Figure 5. Global Head and Neck Cancer Market Share (%), By Drug Class, 2017-2031F
• Figure 6. Global Head and Neck Cancer Market Share (%), By Distribution Channel, 2017-2031F
• Figure 7. Global Head and Neck Cancer Market Share (%), By Region, 2017-2031F
• Figure 8. North America Head and Neck Cancer Market, By Value, In USD Billion, 2017-2031F
• Figure 9. North America Head and Neck Cancer Market, By Volume, In Million Units, 2017-2031F
• Figure 10. North America Head and Neck Cancer Market Share (%), By Therapy Type, 2017-2031F
• Figure 11. North America Head and Neck Cancer Market Share (%), By Route of Administration, 2017-2031F
• Figure 12. North America Head and Neck Cancer Market Share (%), By Drug Class, 2017-2031F
• Figure 13. North America Head and Neck Cancer Market Share (%), By Distribution Channel, 2017-2031F
• Figure 14. North America Head and Neck Cancer Market Share (%), By Country, 2017-2031F
• Figure 15. United States Head and Neck Cancer Market, By Value, In USD Billion, 2017-2031F
• Figure 16. United States Head and Neck Cancer Market, By Volume, In Million Units, 2017-2031F
• Figure 17. United States Head and Neck Cancer Market Share (%), By Therapy Type, 2017-2031F
• Figure 18. United States Head and Neck Cancer Market Share (%), By Route of Administration, 2017-2031F
• Figure 19. United States Head and Neck Cancer Market Share (%), By Drug Class, 2017-2031F
• Figure 20. United States Head and Neck Cancer Market Share (%), By Distribution Channel, 2017-2031F
• Figure 21. Canada Head and Neck Cancer Market, By Value, In USD Billion, 2017-2031F
• Figure 22. Canada Head and Neck Cancer Market, By Volume, In Million Units, 2017-2031F
• Figure 23. Canada Head and Neck Cancer Market Share (%), By Therapy Type, 2017-2031F
• Figure 24. Canada Head and Neck Cancer Market Share (%), By Route of Administration, 2017-2031F
• Figure 25. Canada Head and Neck Cancer Market Share (%), By Drug Class, 2017-2031F
• Figure 26. Canada Head and Neck Cancer Market Share (%), By Distribution Channel, 2017-2031F
• Figure 27. Mexico Head and Neck Cancer Market, By Value, In USD Billion, 2017-2031F
• Figure 28. Mexico Head and Neck Cancer Market, By Volume, In Million Units, 2017-2031F
• Figure 29. Mexico Head and Neck Cancer Market Share (%), By Therapy Type, 2017-2031F
• Figure 30. Mexico Head and Neck Cancer Market Share (%), By Route of Administration, 2017-2031F
• Figure 31. Mexico Head and Neck Cancer Market Share (%), By Drug Class, 2017-2031F
• Figure 32. Mexico Head and Neck Cancer Market Share (%), By Distribution Channel, 2017-2031F
• Figure 33. Europe Head and Neck Cancer Market, By Value, In USD Billion, 2017-2031F
• Figure 34. Europe Head and Neck Cancer Market, By Volume, In Million Units, 2017-2031F
• Figure 35. Europe Head and Neck Cancer Market Share (%), By Therapy Type, 2017-2031F
• Figure 36. Europe Head and Neck Cancer Market Share (%), By Route of Administration, 2017-2031F
• Figure 37. Europe Head and Neck Cancer Market Share (%), By Drug Class, 2017-2031F
• Figure 38. Europe Head and Neck Cancer Market Share (%), By Distribution Channel, 2017-2031F
• Figure 39. Europe Head and Neck Cancer Market Share (%), By Country, 2017-2031F
• Figure 40. Germany Head and Neck Cancer Market, By Value, In USD Billion, 2017-2031F
• Figure 41. Germany Head and Neck Cancer Market, By Volume, In Million Units, 2017-2031F
• Figure 42. Germany Head and Neck Cancer Market Share (%), By Therapy Type, 2017-2031F
• Figure 43. Germany Head and Neck Cancer Market Share (%), By Route of Administration, 2017-2031F
• Figure 44. Germany Head and Neck Cancer Market Share (%), By Drug Class, 2017-2031F
• Figure 45. Germany Head and Neck Cancer Market Share (%), By Distribution Channel, 2017-2031F
• Figure 46. France Head and Neck Cancer Market, By Value, In USD Billion, 2017-2031F
• Figure 47. France Head and Neck Cancer Market, By Volume, In Million Units, 2017-2031F
• Figure 48. France Head and Neck Cancer Market Share (%), By Therapy Type, 2017-2031F
• Figure 49. France Head and Neck Cancer Market Share (%), By Route of Administration, 2017-2031F
• Figure 50. France Head and Neck Cancer Market Share (%), By Drug Class, 2017-2031F
• Figure 51. France Head and Neck Cancer Market Share (%), By Distribution Channel, 2017-2031F
• Figure 52. Italy Head and Neck Cancer Market, By Value, In USD Billion, 2017-2031F
• Figure 53. Italy Head and Neck Cancer Market, By Volume, In Million Units, 2017-2031F
• Figure 54. Italy Head and Neck Cancer Market Share (%), By Therapy Type, 2017-2031F
• Figure 55. Italy Head and Neck Cancer Market Share (%), By Route of Administration, 2017-2031F
• Figure 56. Italy Head and Neck Cancer Market Share (%), By Drug Class, 2017-2031F
• Figure 57. Italy Head and Neck Cancer Market Share (%), By Distribution Channel, 2017-2031F
• Figure 58. United Kingdom Head and Neck Cancer Market, By Value, In USD Billion, 2017-2031F
• Figure 59. United Kingdom Head and Neck Cancer Market, By Volume, In Million Units, 2017-2031F
• Figure 60. United Kingdom Head and Neck Cancer Market Share (%), By Therapy Type, 2017-2031F
• Figure 61. United Kingdom Head and Neck Cancer Market Share (%), By Route of Administration, 2017-2031F
• Figure 62. United Kingdom Head and Neck Cancer Market Share (%), By Drug Class, 2017-2031F
• Figure 63. United Kingdom Head and Neck Cancer Market Share (%), By Distribution Channel, 2017-2031F
• Figure 64. Russia Head and Neck Cancer Market, By Value, In USD Billion, 2017-2031F
• Figure 65. Russia Head and Neck Cancer Market, By Volume, In Million Units, 2017-2031F
• Figure 66. Russia Head and Neck Cancer Market Share (%), By Therapy Type, 2017-2031F
• Figure 67. Russia Head and Neck Cancer Market Share (%), By Route of Administration, 2017-2031F
• Figure 68. Russia Head and Neck Cancer Market Share (%), By Drug Class, 2017-2031F
• Figure 69. Russia Head and Neck Cancer Market Share (%), By Distribution Channel, 2017-2031F
• Figure 70. Netherlands Head and Neck Cancer Market, By Value, In USD Billion, 2017-2031F
• Figure 71. Netherlands Head and Neck Cancer Market, By Volume, In Million Units, 2017-2031F
• Figure 72. Netherlands Head and Neck Cancer Market Share (%), By Therapy Type, 2017-2031F
• Figure 73. Netherlands Head and Neck Cancer Market Share (%), By Route of Administration, 2017-2031F
• Figure 74. Netherlands Head and Neck Cancer Market Share (%), By Drug Class, 2017-2031F
• Figure 75. Netherlands Head and Neck Cancer Market Share (%), By Distribution Channel, 2017-2031F
• Figure 76. Spain Head and Neck Cancer Market, By Value, In USD Billion, 2017-2031F
• Figure 77. Spain Head and Neck Cancer Market, By Volume, In Million Units, 2017-2031F
• Figure 78. Spain Head and Neck Cancer Market Share (%), By Therapy Type, 2017-2031F
• Figure 79. Spain Head and Neck Cancer Market Share (%), By Route of Administration, 2017-2031F
• Figure 80. Spain Head and Neck Cancer Market Share (%), By Drug Class, 2017-2031F
• Figure 81. Spain Head and Neck Cancer Market Share (%), By Distribution Channel, 2017-2031F
• Figure 82. Turkey Head and Neck Cancer Market, By Value, In USD Billion, 2017-2031F
• Figure 83. Turkey Head and Neck Cancer Market, By Volume, In Million Units, 2017-2031F
• Figure 84. Turkey Head and Neck Cancer Market Share (%), By Therapy Type, 2017-2031F
• Figure 85. Turkey Head and Neck Cancer Market Share (%), By Route of Administration, 2017-2031F
• Figure 86. Turkey Head and Neck Cancer Market Share (%), By Drug Class, 2017-2031F
• Figure 87. Turkey Head and Neck Cancer Market Share (%), By Distribution Channel, 2017-2031F
• Figure 88. Poland Head and Neck Cancer Market, By Value, In USD Billion, 2017-2031F
• Figure 89. Poland Head and Neck Cancer Market, By Volume, In Million Units, 2017-2031F
• Figure 90. Poland Head and Neck Cancer Market Share (%), By Therapy Type, 2017-2031F
• Figure 91. Poland Head and Neck Cancer Market Share (%), By Route of Administration, 2017-2031F
• Figure 92. Poland Head and Neck Cancer Market Share (%), By Drug Class, 2017-2031F
• Figure 93. Poland Head and Neck Cancer Market Share (%), By Distribution Channel, 2017-2031F
• Figure 94. South America Head and Neck Cancer Market, By Value, In USD Billion, 2017-2031F
• Figure 95. South America Head and Neck Cancer Market, By Volume, In Million Units, 2017-2031F
• Figure 96. South America Head and Neck Cancer Market Share (%), By Therapy Type, 2017-2031F
• Figure 97. South America Head and Neck Cancer Market Share (%), By Route of Administration, 2017-2031F
• Figure 98. South America Head and Neck Cancer Market Share (%), By Drug Class, 2017-2031F
• Figure 99. South America Head and Neck Cancer Market Share (%), By Distribution Channel, 2017-2031F
• Figure 100. South America Head and Neck Cancer Market Share (%), By Country, 2017-2031F
• Figure 101. Brazil Head and Neck Cancer Market, By Value, In USD Billion, 2017-2031F
• Figure 102. Brazil Head and Neck Cancer Market, By Volume, In Million Units, 2017-2031F
• Figure 103. Brazil Head and Neck Cancer Market Share (%), By Therapy Type, 2017-2031F
• Figure 104. Brazil Head and Neck Cancer Market Share (%), By Route of Administration, 2017-2031F
• Figure 105. Brazil Head and Neck Cancer Market Share (%), By Drug Class, 2017-2031F
• Figure 106. Brazil Head and Neck Cancer Market Share (%), By Distribution Channel, 2017-2031F
• Figure 107. Argentina Head and Neck Cancer Market, By Value, In USD Billion, 2017-2031F
• Figure 108. Argentina Head and Neck Cancer Market, By Volume, In Million Units, 2017-2031F
• Figure 109. Argentina Head and Neck Cancer Market Share (%), By Therapy Type, 2017-2031F
• Figure 110. Argentina Head and Neck Cancer Market Share (%), By Route of Administration, 2017-2031F
• Figure 111. Argentina Head and Neck Cancer Market Share (%), By Drug Class, 2017-2031F
• Figure 112. Argentina Head and Neck Cancer Market Share (%), By Distribution Channel, 2017-2031F
• Figure 113. Asia-Pacific Head and Neck Cancer Market, By Value, In USD Billion, 2017-2031F
• Figure 114. Asia-Pacific Head and Neck Cancer Market, By Volume, In Million Units, 2017-2031F
• Figure 115. Asia-Pacific Head and Neck Cancer Market Share (%), By Therapy Type, 2017-2031F
• Figure 116. Asia-Pacific Head and Neck Cancer Market Share (%), By Route of Administration, 2017-2031F
• Figure 117. Asia-Pacific Head and Neck Cancer Market Share (%), By Drug Class, 2017-2031F
• Figure 118. Asia-Pacific Head and Neck Cancer Market Share (%), By Distribution Channel, 2017-2031F
• Figure 119. Asia-Pacific Head and Neck Cancer Market Share (%), By Country, 2017-2031F
• Figure 120. India Head and Neck Cancer Market, By Value, In USD Billion, 2017-2031F
• Figure 121. India Head and Neck Cancer Market, By Volume, In Million Units, 2017-2031F
• Figure 122. India Head and Neck Cancer Market Share (%), By Therapy Type, 2017-2031F
• Figure 123. India Head and Neck Cancer Market Share (%), By Route of Administration, 2017-2031F
• Figure 124. India Head and Neck Cancer Market Share (%), By Drug Class, 2017-2031F
• Figure 125. India Head and Neck Cancer Market Share (%), By Distribution Channel, 2017-2031F
• Figure 126. China Head and Neck Cancer Market, By Value, In USD Billion, 2017-2031F
• Figure 127. China Head and Neck Cancer Market, By Volume, In Million Units, 2017-2031F
• Figure 128. China Head and Neck Cancer Market Share (%), By Therapy Type, 2017-2031F
• Figure 129. China Head and Neck Cancer Market Share (%), By Route of Administration, 2017-2031F
• Figure 130. China Head and Neck Cancer Market Share (%), By Drug Class, 2017-2031F
• Figure 131. China Head and Neck Cancer Market Share (%), By Distribution Channel, 2017-2031F
• Figure 132. Japan Head and Neck Cancer Market, By Value, In USD Billion, 2017-2031F
• Figure 133. Japan Head and Neck Cancer Market, By Volume, In Million Units, 2017-2031F
• Figure 134. Japan Head and Neck Cancer Market Share (%), By Therapy Type, 2017-2031F
• Figure 135. Japan Head and Neck Cancer Market Share (%), By Route of Administration, 2017-2031F
• Figure 136. Japan Head and Neck Cancer Market Share (%), By Drug Class, 2017-2031F
• Figure 137. Japan Head and Neck Cancer Market Share (%), By Distribution Channel, 2017-2031F
• Figure 138. Australia Head and Neck Cancer Market, By Value, In USD Billion, 2017-2031F
• Figure 139. Australia Head and Neck Cancer Market, By Volume, In Million Units, 2017-2031F
• Figure 140. Australia Head and Neck Cancer Market Share (%), By Therapy Type, 2017-2031F
• Figure 141. Australia Head and Neck Cancer Market Share (%), By Route of Administration, 2017-2031F
• Figure 142. Australia Head and Neck Cancer Market Share (%), By Drug Class, 2017-2031F
• Figure 143. Australia Head and Neck Cancer Market Share (%), By Distribution Channel, 2017-2031F
• Figure 144. Vietnam Head and Neck Cancer Market, By Value, In USD Billion, 2017-2031F
• Figure 145. Vietnam Head and Neck Cancer Market, By Volume, In Million Units, 2017-2031F
• Figure 146. Vietnam Head and Neck Cancer Market Share (%), By Therapy Type, 2017-2031F
• Figure 147. Vietnam Head and Neck Cancer Market Share (%), By Route of Administration, 2017-2031F
• Figure 148. Vietnam Head and Neck Cancer Market Share (%), By Drug Class, 2017-2031F
• Figure 149. Vietnam Head and Neck Cancer Market Share (%), By Distribution Channel, 2017-2031F
• Figure 150. South Korea Head and Neck Cancer Market, By Value, In USD Billion, 2017-2031F
• Figure 151. South Korea Head and Neck Cancer Market, By Volume, In Million Units, 2017-2031F
• Figure 152. South Korea Head and Neck Cancer Market Share (%), By Therapy Type, 2017-2031F
• Figure 153. South Korea Head and Neck Cancer Market Share (%), By Route of Administration, 2017-2031F
• Figure 154. South Korea Head and Neck Cancer Market Share (%), By Drug Class, 2017-2031F
• Figure 155. South Korea Head and Neck Cancer Market Share (%), By Distribution Channel, 2017-2031F
• Figure 156. Indonesia Head and Neck Cancer Market, By Value, In USD Billion, 2017-2031F
• Figure 157. Indonesia Head and Neck Cancer Market, By Volume, In Million Units, 2017-2031F
• Figure 158. Indonesia Head and Neck Cancer Market Share (%), By Therapy Type, 2017-2031F
• Figure 159. Indonesia Head and Neck Cancer Market Share (%), By Route of Administration, 2017-2031F
• Figure 160. Indonesia Head and Neck Cancer Market Share (%), By Drug Class, 2017-2031F
• Figure 161. Indonesia Head and Neck Cancer Market Share (%), By Distribution Channel, 2017-2031F
• Figure 162. Philippines Head and Neck Cancer Market, By Value, In USD Billion, 2017-2031F
• Figure 163. Philippines Head and Neck Cancer Market, By Volume, In Million Units, 2017-2031F
• Figure 164. Philippines Head and Neck Cancer Market Share (%), By Therapy Type, 2017-2031F
• Figure 165. Philippines Head and Neck Cancer Market Share (%), By Route of Administration, 2017-2031F
• Figure 166. Philippines Head and Neck Cancer Market Share (%), By Drug Class, 2017-2031F
• Figure 167. Philippines Head and Neck Cancer Market Share (%), By Distribution Channel, 2017-2031F
• Figure 168. Middle East & Africa Head and Neck Cancer Market, By Value, In USD Billion, 2017-2031F
• Figure 169. Middle East & Africa Head and Neck Cancer Market, By Volume, In Million Units, 2017-2031F
• Figure 170. Middle East & Africa Head and Neck Cancer Market Share (%), By Therapy Type, 2017-2031F
• Figure 171. Middle East & Africa Head and Neck Cancer Market Share (%), By Route of Administration, 2017-2031F
• Figure 172. Middle East & Africa Head and Neck Cancer Market Share (%), By Drug Class, 2017-2031F
• Figure 173. Middle East & Africa Head and Neck Cancer Market Share (%), By Distribution Channel, 2017-2031F
• Figure 174. Middle East & Africa Head and Neck Cancer Market Share (%), By Country, 2017-2031F
• Figure 175. Saudi Arabia Head and Neck Cancer Market, By Value, In USD Billion, 2017-2031F
• Figure 176. Saudi Arabia Head and Neck Cancer Market, By Volume, In Million Units, 2017-2031F
• Figure 177. Saudi Arabia Head and Neck Cancer Market Share (%), By Therapy Type, 2017-2031F
• Figure 178. Saudi Arabia Head and Neck Cancer Market Share (%), By Route of Administration, 2017-2031F
• Figure 179. Saudi Arabia Head and Neck Cancer Market Share (%), By Drug Class, 2017-2031F
• Figure 180. Saudi Arabia Head and Neck Cancer Market Share (%), By Distribution Channel, 2017-2031F
• Figure 181. UAE Head and Neck Cancer Market, By Value, In USD Billion, 2017-2031F
• Figure 182. UAE Head and Neck Cancer Market, By Volume, In Million Units, 2017-2031F
• Figure 183. UAE Head and Neck Cancer Market Share (%), By Therapy Type, 2017-2031F
• Figure 184. UAE Head and Neck Cancer Market Share (%), By Route of Administration, 2017-2031F
• Figure 185. UAE Head and Neck Cancer Market Share (%), By Drug Class, 2017-2031F
• Figure 186. UAE Head and Neck Cancer Market Share (%), By Distribution Channel, 2017-2031F
• Figure 187. South Africa Head and Neck Cancer Market, By Value, In USD Billion, 2017-2031F
• Figure 188. South Africa Head and Neck Cancer Market, By Volume, In Million Units, 2017-2031F
• Figure 189. South Africa Head and Neck Cancer Market Share (%), By Therapy Type, 2017-2031F
• Figure 190. South Africa Head and Neck Cancer Market Share (%), By Route of Administration, 2017-2031F
• Figure 191. South Africa Head and Neck Cancer Market Share (%), By Drug Class, 2017-2031F
• Figure 192. South Africa Head and Neck Cancer Market Share (%), By Distribution Channel, 2017-2031F
• Figure 193. By Therapy Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 194. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 195. By Drug Class Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 196. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 197. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023